Ascorbate exerts anti-proliferative effects through cell cycle inhibition and sensitizes tumor cells towards cytostatic drugs
/in International Publications, MicronutrientsGlobal sensitivity analysis and model-based reactive scheduling of targeted cancer immunotherapy
/in Dendritic Cells, International Publications[Auto-dendritic cell vaccines pulsed with PSA, PSMA and PAP peptides for hormone-refractory prostate cancer]
/in Dendritic Cells, International Publications, Prostate CancerProstate cancer as a model for tumour immunotherapy
/in Dendritic Cells, International Publications, Prostate Cancer[Progress in using Newcastle disease virus for tumor therapy: a review]
/in International Publications, Newcastle Disease Virus[Anti-tumor immunity of Newcastle disease virus HN protein is influenced by differential subcellular targeting]
/in International Publications, Newcastle Disease VirusHyperthermia potentiates oncolytic herpes viral killing of pancreatic cancer through a heat shock protein pathway
/in Hyperthermia, International Publications, Newcastle Disease Virus, Pancreatic CancerDendritic cell vaccination in human melanoma: relationships between clinical effects and vaccine parameters
/in Dendritic Cells, International Publications, Malignant MelanomaHuman myeloid dendritic cells for cancer therapy: does maturation matter?
/in Dendritic Cells, International Publications
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer